| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443503 | European Journal of Cancer | 2014 | 11 Pages |
Abstract
Combination docetaxel + vandetanib did not prolong PFS relative to docetaxel alone in OC patients. No unexpected safety issues were identified.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Robert L. Coleman, James Moon, Anil K. Sood, Wei Hu, James E. Delmore, Albert J. Bonebrake, Garnet L. Anderson, Setsuko K. Chambers, Maurie Markman,